| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2023 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 23 Nov 2022 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the press release related to the first nine months of 2022 financial results | Download |
| 04 Nov 2022 | On business and financial situation | The Company releases the first nine months 2022 financial results presentation | Download |
| 15 Mar 2022 | On significant placements in financial instruments | Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 17 Dec 2021 | On business and financial situation | ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia | Download |
| 13 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 | Download |
| 06 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 | Download |
| 22 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 November 2021 and 19 November 2021 | Download |
| 16 Nov 2021 | Liquidity and counterparty agreements | The Company informs of the termination of the Liquidity Agreement | Download |